Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Following this development, the company’s tenapanor (branded as Xphozah) drug now has a very high chance of obtaining approval for use as a treatment for chronic kidney disease, which explains why ARDX stock has nearly tripled in price since November.
Source: https://investorplace.com/market360/2023/02/7-a-rated-stocks-to-buy-for-february-2023/
The boost came from its successful launch of Ibsrela, which is the brand name for tenapanor to treat irritable bowel syndrome.
Source: https://investorplace.com/market360/2023/03/7-core-stocks-to-buy-to-build-a-solid-portfolio-around/
This is now all about revenue, and so far, in the one marketed indication, tenapanor has done very well.